Fractyl Health (GUTS) Return on Capital Employed (2024 - 2026)
Fractyl Health's (GUTS) quarterly Return on Capital Employed came in at 97.78% in Q1 2026, up 2826.0% YoY from 3.34% in Q1 2025, and little changed on a QoQ basis from 97.29% in Q4 2025.
Fractyl Health (GUTS) Return on Capital Employed (2024 - 2026) Analysis & Trends
Fractyl Health (GUTS) has 3 years of Return on Capital Employed data on file, last reported at 97.78% in Q1 2026.
- Quarterly Return on Capital Employed rose 2826.0% year-over-year to 97.78% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 97.78% (up 2826.0% YoY) and the FY2025 annual result came in at 100.42%, up 2882.0% from the prior year.
- Return on Capital Employed steadied at 97.78% in Q1 2026, from 97.29% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 50.73% in Q2 2024 to a low of 196.96% in Q2 2025.
- A 3-year average of 103.38% and a median of 97.29% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed plunged 14623 bps — and 2026, when it surged 2826 bps.
- Tracing GUTS's Return on Capital Employed over 3 years: stood at 95.71% in 2024, then dropped by 2 bps to 97.29% in 2025, then decreased by 0 bps to 97.78% in 2026.
- The last three Return on Capital Employed figures came in at 97.78% (Q1 2026), 97.29% (Q4 2025), and 142.16% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 7.88% |
| 10 | Fractyl Health | 124.02 Mn | 124.02 Mn | - | -114.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -114.61% |
| Mar 31, 2026 | -97.78% |
| Dec 31, 2025 | -97.29% |
| Sep 30, 2025 | -142.16% |
| Jun 30, 2025 | -196.96% |
| Mar 31, 2025 | -126.04% |
| Dec 31, 2024 | -95.71% |
| Sep 30, 2024 | -67.21% |
| Jun 30, 2024 | -50.73% |
| Mar 31, 2024 | -56.54% |